CEOLIVE Interviews CEO’s & Executives from publicly traded companies and start-ups.

CEORoadshow Interview: Hemispherx (NYSE American:HEB) Reports Positive Safety and Survival Data
August 15
CEO Interviews

In this interview, Mr. Equels discusses the company's latest news regarding positive safety data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®.

U.S. Gold Corp. $USAU is a Gold Exploration Play with Massive Upside Potential
July 29
CEO InterviewsCEORoadshow

In this episode of CEO Roadshow we are joined by Mr. Edward Karr, CEO of US Gold Corp, ticker USAU, a publicly-traded, U.S. focused gold exploration and development Company.

My Size (MYSZ) Technology Integrated with Global Apparal E-Commerce Platform
July 25
CEO InterviewsCEORoadshow

In this episode of CEO Roadshow, we’re joined by Mr. Ronen Luzon, Founder and CEO of MySize, Inc., Founder, and CEO of My Size, the developer and creator of smartphone measurement solutions.

CEORoadshow Interviews CEO of Sify Technologies, a Top Ranked ICT Firm in India
July 25
CEO Interviews

In this episode of CEO Roadshow, we’re joined by Mr. Kamal Nath, CEO of Sify Technologies Limited, which provides integrated ICT solutions and services internationally.

CEOLIVE Profiles Up and Coming Innovative Companies

Quarterly Report Shows That Hemispherx Biopharma (NYSEMKT:HEB) Has a Unique Opportunity for Investors as it Continues to Make Strong Progress with Multiple Clinical Trials in 2019
May 21
Company ProfilesNewsNews

The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade, according to researchers.

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
May 13
Biotech StocksCompany Profiles

According to the latest news from the company, Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.

Which ESports Stocks You Should Be Watching and Why?
April 01
CEO InterviewsCEOLIVE WatchlistCompany ProfilesTechnology Stocks

Esports is entering a tremendous growth phase. The global esports economy is expected to grow to more than $905 million this year, according to market research firm Newzoo. That figure would represent year-over-year growth of roughly 38%.


Lost your password?